AGING CELL:改变神经代谢可促进蛋白质稳态和长寿

2019-03-01 海北 MedSci原创

衰老与组织和代谢稳态的进行性丧失有关。已有的研究显示,这种损失可以通过单基因扰动延迟,从而延长寿命。但是至今为止,我们对于这种扰动如何影响代谢和保护机体网络,以延长寿命仍不清楚。

衰老与组织和代谢稳态的进行性丧失有关。已有的研究显示,这种损失可以通过单基因扰动延迟,从而延长寿命。但是至今为止,我们对于这种扰动如何影响代谢和保护机体网络,以延长寿命仍不清楚。

最近,研究人员通过全面描述果蝇大脑中蛋白质周转率的年龄相关变化,以及具有升高的Jun-N末端激酶信号传导的长寿动物的神经元代谢组,转录组和碳通量的变化来解决这个问题 。

研究人员发现,这些动物表现出延迟的年龄相关的蛋白质周转率的下降,以及稳态神经元葡萄糖-6-磷酸水平的降低,和由于葡萄糖-6-磷酸脱氢酶(G6PD)的诱导导致的进入戊糖磷酸途径的碳通量的增加。

在神经元中过度表达G6PD足以重现这些代谢和蛋白质稳态变化,并延长寿命。

因此,该研究确定了代谢变化与神经元中改善的蛋白质稳态之间的联系,这有助于长寿突变体的寿命延长。


原始出处:

Lifen Wang et al. JNK modifies neuronal metabolism to promote proteostasis and longevity. Aging Cell, 2019; doi: https://doi.org/10.1111/acel.12849


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1871176, encodeId=c62c18e1176da, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Dec 06 16:14:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765765, encodeId=92f41e6576502, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Dec 18 16:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646733, encodeId=b2a41646e33fe, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Sun Nov 03 13:14:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961454, encodeId=b60e196145433, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 05 10:14:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297073, encodeId=55c2129e07308, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Mar 02 23:14:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1871176, encodeId=c62c18e1176da, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Dec 06 16:14:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765765, encodeId=92f41e6576502, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Dec 18 16:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646733, encodeId=b2a41646e33fe, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Sun Nov 03 13:14:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961454, encodeId=b60e196145433, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 05 10:14:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297073, encodeId=55c2129e07308, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Mar 02 23:14:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1871176, encodeId=c62c18e1176da, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Dec 06 16:14:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765765, encodeId=92f41e6576502, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Dec 18 16:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646733, encodeId=b2a41646e33fe, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Sun Nov 03 13:14:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961454, encodeId=b60e196145433, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 05 10:14:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297073, encodeId=55c2129e07308, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Mar 02 23:14:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
    2019-11-03 changfy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1871176, encodeId=c62c18e1176da, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Dec 06 16:14:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765765, encodeId=92f41e6576502, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Dec 18 16:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646733, encodeId=b2a41646e33fe, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Sun Nov 03 13:14:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961454, encodeId=b60e196145433, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 05 10:14:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297073, encodeId=55c2129e07308, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Mar 02 23:14:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
    2019-04-05 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=1871176, encodeId=c62c18e1176da, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Dec 06 16:14:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765765, encodeId=92f41e6576502, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Dec 18 16:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646733, encodeId=b2a41646e33fe, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Sun Nov 03 13:14:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961454, encodeId=b60e196145433, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 05 10:14:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297073, encodeId=55c2129e07308, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Mar 02 23:14:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]

相关资讯

PNAS:不得已再剖吧!科学家发现剖宫产影响大脑发育和后代行为的机制,或与失去顺产对大脑神经的保护有关

来自乔治亚州立大学神经科学研究所的Nancy G. Forger教授探究了不同出生方式对小鼠不同大脑区域神经细胞的影响。结果表明,在小鼠大脑发育的重要时期,剖宫产出生的小鼠神经细胞死亡率高于阴道分娩出生的小鼠。

年终盘点:2018年神经领域重磅级亮点研究成果

美好的2018又快接近年底,继2008年北京奥运会成功举办后的十年里,中国的房价达到了不可逾越的高度,科学技术的发展在这十年里也经历了质的飞跃,我国的医疗技术和科研水平都得到了切实的提高。让我们来盘点一下今年神经领域中又有哪些新奇有趣的为人类谋福祉的大事发生吧。神经病学顾问哈里·李·帕克(Harry Lee Parker)将他的医学生比作干瘪的新手,这之中隐藏着医学生们对神经病学的恐惧

神经垂体颗粒细胞瘤1例

男,45岁,因头痛伴视力下降1年、加重1月余入院。1年前无明显诱因出现头痛,以额顶部显著,呈阵发性胀痛,可忍受,伴视力下降、视物模糊、性功能障碍,未系统诊治。1个月前头痛加重,视力下降较前加重并出现双眼同侧暗点。

JACC:主动脉瓣置换术后神经并发症的比较

主动脉瓣置换术后神经并发症会增加患者的死亡风险,经导管主动脉瓣置换术(TAVR)的开展在低外科风险的严重主动脉瓣狭窄患者中已经越来越普遍。本研究的目的旨在评估SURTAVI临床试验中的神经并发症。本研究将中度外科风险有临床症状的严重主动脉瓣狭窄患者(平均年龄79.8 ± 6.2岁,n=1660)1:1随机分至经皮导管主动脉瓣置换(TAVR)组和外科主动脉瓣置换(SAVR)组。分析结果显示,早期(术

中西医结合治疗抑郁症研究新进展

目前抑郁症多采用西药治疗,但常规西药治疗有效率和治愈率分别在64%、30%左右,特别是难治性抑郁症,由于治疗效果差且患者恢复社会功能不良,而成为临床上的一大难题。目前越来越多的研究将中西医药物联合应用治疗抑郁,用药治疗越早,临床效果越好,不良反应少,现将中西医结合治疗研究进展作一综述。

Biol Psychiat:有趣!一种药物,或能促进长期记忆

近日,一项非常引人入胜的研究表明,服用一种能增加大脑中组胺水平的药物可以改善长期记忆的能力。